Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with diagnosis of MPS II based on both clinical and biochemical criteria~2. Male, ages 6 to 35 years old~3. Patients who are able to comply with the study requirements~4. Patients who have given voluntary written consent to participate in the study~5. Patients who is acceptable for using an appropriate method of contraception~Exclusion Criteria:~1. History of a tracheostomy or a bone marrow transplant~2. Known hypersensitivity to idursulfase~3. Known shock to idursulfase~4. History of receiving treatment with another investigational therapy within the past 30 days~5. History of a stem cell transplant~6. Known hypersensitivity to any of the components of idursulfase~7. Female

- Gender: MALE
- Minimum Age: 6 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- GC1111_0.5mg/kg (Type: EXPERIMENTAL): None
- GC1111_1.0mg/kg (Type: EXPERIMENTAL): None
- Elaprase_0.5mg/kg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).